Assuntos
Doenças Autoimunes/tratamento farmacológico , COVID-19/patologia , Fatores Imunológicos/efeitos adversos , Fatores Imunológicos/uso terapêutico , Rituximab/efeitos adversos , Rituximab/uso terapêutico , Idoso , Antígenos CD20/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , SARS-CoV-2/imunologia , Carga Viral/efeitos dos fármacosRESUMO
PURPOSE: We evaluated the interest of systematic screening of serum fungal markers in patients hospitalized in a medical ward. METHODS: We retrospectively analyzed all patients hospitalized in our infectious disease department from October 1st to October 31st, 2020 for COVID-19 without prior ICU admission, and for whom systematic screening of serum fungal markers was performed. RESULTS: Thirty patients were included. The majority of patients received corticosteroids (96.7%). The galactomannan antigen assay was positive for 1/30 patients at D0, and 0/24, 0/16, 0/13 and 0/2 at D4, D7, D10 and D14 respectively. 1,3-ß-D-glucan was positive for 0/30, 1/24, 1/12, 0/12, 0/2 at D0, D4, D7, D10 and D14 respectively. No Aspergillus fumigatus PCR was positive. No cases of aspergillosis were retained. CONCLUSION: Our study does not support the interest of systematic screening of fungal markers in immunocompetent patients with COVID-19 in a conventional unit.